The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prevalence of fibroadenoma-like areas in malignant phyllodes tumors of the breast: A retrospective analysis from a referral center.
 
Carmine Valenza
No Relationships to Disclose
 
Edoardo Olmeda
No Relationships to Disclose
 
Francesca Maria Porta
No Relationships to Disclose
 
Tommaso Martino De Pas
No Relationships to Disclose
 
Aurora Gaeta
No Relationships to Disclose
 
Grazia Castellano
No Relationships to Disclose
 
Celeste Santoro
No Relationships to Disclose
 
Elena Battaiotto
No Relationships to Disclose
 
Giulia Chiappini
No Relationships to Disclose
 
Dario Trapani
No Relationships to Disclose
 
Sara Coppola
No Relationships to Disclose
 
Fabio Conforti
No Relationships to Disclose
 
Denise Mattar
No Relationships to Disclose
 
Sara Gandini
No Relationships to Disclose
 
Paolo Veronesi
No Relationships to Disclose
 
Elena Guerini Rocco
No Relationships to Disclose
 
Elisabetta Pennacchioli
No Relationships to Disclose
 
Giuseppe Curigliano
Leadership - ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech